Antimicrobial Spectrum and Clinical Application of Cefazolin and Clavulin

Introduction to Antimicrobial Coverage

Clavulin (amoxicillin-clavulanate) has broader antimicrobial coverage than cefazolin, particularly against anaerobes and beta-lactamase producing organisms, making it more appropriate for polymicrobial infections involving gram-negative and anaerobic bacteria 1, 2

Cefazolin has excellent activity against methicillin-sensitive Staphylococcus aureus (MSSA) 3
Cefazolin has good coverage of beta-lactam susceptible streptococci 1
Cefazolin has no enterococcal coverage 1, 4
Cefazolin has limited gram-negative coverage, mainly against basic enteric gram-negative organisms like E. coli in community settings 1, 2
Cefazolin has no anaerobic coverage, requiring combination with metronidazole for infections involving Bacteroides fragilis and other obligate anaerobes 1, 2

Clavulin covers MSSA and streptococci 5, 6
Clavulin has limited enterococcal activity, only against ampicillin-susceptible strains 4
Clavulin has broader gram-negative coverage than cefazolin, including beta-lactamase producing E. coli, Klebsiella, and other Enterobacteriaceae 2, 7
Clavulin has excellent anaerobic coverage, including Bacteroides fragilis, with approximately 70% susceptibility rate 1, 2, 7

The Infectious Diseases Society of America recommends cefazolin for MSSA skin and soft tissue infections where narrower spectrum is adequate 1
The American College of Surgeons recommends cefazolin for surgical prophylaxis in clean or clean-contaminated procedures, although the specific guideline is not provided in the text 1
Clavulin is preferred for mild-to-moderate community-acquired intra-abdominal infections requiring single-agent therapy with anaerobic coverage 1, 2
The International Working Group on the Diabetic Foot recommends clavulin for diabetic foot infections (moderate severity) where gram-negative and anaerobic coverage is needed 5

Local resistance patterns must be reviewed before using amoxicillin-clavulanate, as E. coli resistance is increasing 2
B. fragilis resistance to clavulanate-containing regimens is approximately 30%, which may require alternative therapy 7
Cefazolin is generally less expensive and has narrower spectrum, making it preferable when adequate 1, 2
Amoxicillin-clavulanate is associated with higher rates of drug-induced liver injury (DILI) compared to cefazolin 6
Cefazolin requires metronidazole addition for anaerobic coverage in intra-abdominal infections 1, 2
Clavulin can be used as monotherapy for mild-to-moderate community-acquired infections with anaerobic involvement 1, 2